A symmetry-based search paired with molecular-dynamics calculations using a universal machine-learning force field identified five oxygen-, four lithium- and three sodium-based superionic conductor candidates. The authors report simulated diffusion properties comparable to leading materials and connected diffusion pathways. These are computational predictions; the study abstract does not establish experimental synthesis or measured ionic conductivity.
Technology: Universal machine-learning force field for molecular-dynamics screening
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The primary abstract reports molecular-dynamics screening with a universal machine-learning force field and identifies five oxygen-, four lithium- and three sodium-based candidates with simulated diffusion comparable to leading materials.
- Still unknown: No experimental synthesis or measured conductivity is established by the reviewed abstract. The symmetry-based search idea is human-derived; the learned force field supports screening and calculated diffusion.
- AI role: A universal machine-learning force field was used in molecular-dynamics simulations that screened and evaluated the reported conductor candidates.
Evidence sources: https://pubs.acs.org/doi/10.1021/acs.chemmater.6c01341
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary publisher indexed abstract, article history, affiliation block and supporting-information listing; full article body not accessible in direct page fetch..
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An LLM agent (Qiushi Discovery Engine) given only the topic optical computing for AI ran an open-ended study of 145.9 million tokens, 3,242 LLM calls and 1,242 tool calls, and proposed an optical bilinear interaction analogous to the attention operation in Transformers, which the authors say they experimentally validated. The abstract gives no accuracy figure or number of experimental runs. This is an arXiv preprint and the validation is reported by the authors themselves.
Technology: Qiushi Discovery Engine (dual-layer LLM agent with Meta-Trace memory)
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The abstract says the proposed optical bilinear interaction was experimentally validated on a real optical platform; it gives no measurement details, trial counts or statistics.
- Still unknown: The abstract gives no validation figures and hedges novelty with 'to our knowledge'; hardware use is framed only as a possible route.
- AI role: An LLM-based agentic system (Qiushi Discovery Engine) ran an open-ended study (3,242 LLM calls, 1,242 tool calls, 163 research notes, 44 scripts) and proposed the mechanism.
Evidence sources: https://arxiv.org/abs/2604.27092
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers designed four protein exoframe modulators targeting the transmembrane region of the dopamine D1 receptor. Structural studies and functional assays showed agonist-positive, negative and biased allosteric modulation; an agonist-positive modulator restored activity in loss-of-function receptor mutants. The journal abstract supports these receptor-level experiments, rather than a clinical treatment claim.
Technology: Computational de novo protein design (AI-based protein design pipeline)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Structural and functional investigation of four designed modulators of the D1 receptor, including rescue of loss-of-function mutants.
- Still unknown: Review limited to abstract, online date and affiliations. Therapeutic efficacy in patients is not established by these receptor experiments.
- AI role: A deep-learning, hallucination-like protein-design workflow used structural prompts to generate transmembrane binding modes.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A%2210.1038%2Fs41586-025-09957-1%22&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
PolyCLOVER integrated multi-stage learning, active learning and high-throughput experiments across a ~100,000-member poly(β-amino ester) space, identifying three lead nanoparticles with measured antibacterial activity and in-vivo mouse outcomes. Mouse groups were small; this does not establish human efficacy or safety.
Technology: Multi-stage self-supervised learning and active learning coupled to high-throughput experimentation
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary Nature abstract/full text reports experimental MICs of 4 and 8 μg/mL against named resistant bacteria and mouse infection models; this is one study, not three discoveries.
- Still unknown: Independent replication and exhaustive prior-art review are not established.
- AI role: Multi-stage self-supervised learning and active learning coupled to high-throughput experimentation
Evidence sources: https://www.nature.com/articles/s41467-026-68682-z
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary source checked for study identity, stated AI contribution, date and bounded result..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An automated Design-Build-Test-Learn campaign applied machine learning and high-throughput synthesis/characterization to a library of 13,728 polymer combinations. Across four active-learning rounds, the authors selected seven candidates for detailed testing. The leading polymer P7 had a reported MIC of 2 μg/mL and IC20 of 256 μg/mL, and was tested in in-vitro and animal models. These laboratory and preclinical results do not establish clinical efficacy or safety.
Technology: Graph Transformer model with active-learning selection
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The study reports seven top candidates from four active-learning rounds. P7 had MIC 2 μg/mL and IC20 256 μg/mL, with in-vitro characterization and animal-model testing reported by the authors.
- Still unknown: These are laboratory and animal results, not human efficacy or safety. The entry reports the authors’ selection and assay result without a claim of global chemical novelty or clinical readiness.
- AI role: A graph-transformer prediction model and active-learning loop ranked polymer candidates for automated synthesis and antimicrobial/biocompatibility testing.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12769852/ · https://pubmed.ncbi.nlm.nih.gov/41502979/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary PMC indexed full text and NCBI/PubMed metadata/abstract for publication date, affiliations, model, assay outcomes and P7 result..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The November 2024 Nature Communications paper describes six GPT-4 agents guiding copper/TEMPO alcohol oxidation, from literature search through optimization and purification. An agent-assisted scale-up produced 915 mg of product at 86% isolated yield and above 98% purity. Additional reaction tasks were demonstrated. The workflow involved chemists: thin-layer chromatography was performed manually, so this was not fully autonomous synthesis.
Technology: LLM-RDF (six GPT-4 agents)
Family GPT-4: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Physical synthesis, optimization, scale-up and product purification.
- Still unknown: Not assessed: supplements; manual TLC and chemist participation are explicit in the paper.
- AI role: Six GPT-4 agents supported literature, design, execution, analysis, separation and interpretation.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11585555/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 189 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
ClickGen combines reaction-based molecular generation, reinforcement learning and inpainting to generate synthesizable candidate structures. In a PARP1 case study, researchers selected and synthesized three generated lead molecules; two showed nanomolar PARP1 inhibition in vitro, with reported IC50 values of 19.24 ± 1.63 nM and 69.73 ± 14.57 nM. The two compounds also showed antiproliferative activity in several tested cancer cell lines and lower toxicity in the reported normal-cell assays than the most toxic lead compounds.
Technology: ClickGen deep-learning reaction-based molecular generator with reinforcement learning, Monte Carlo tree search and an inpainting generator
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In a PARP1 case study, researchers selected and synthesized three generated lead molecules; two showed nanomolar PARP1 inhibition in vitro, with reported IC50 values of 19.24 ± 1.63 nM and 69.73 ± 14.57 nM.
- Still unknown: Three selected molecules were synthesized and tested in vitro; the article reports two with nanomolar PARP1 inhibition. Cell-line antiproliferative and toxicity assays do not show tumor efficacy or safety in animals or people. The reported IC50 values are from triplicate measurements in the study. This record captures the PARP1 experimental result, not the paper’s model benchmark comparisons.
- AI role: The system generated candidate molecules by assembling reaction-compatible synthons and using reinforcement learning/inpainting to guide novelty and binding-oriented generation. Researchers computationally filtered and selected compounds, synthesized three leads and tested them; PARP1 inhibition and cell effects were experimentally measured, not generated by the model.
Evidence sources: https://www.nature.com/articles/s41467-024-54456-y.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 45 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep-learning system called MitoReID classified drug mechanisms from time-resolved mitochondrial morphology and membrane-potential images. Among its natural-compound predictions, it nominated epicatechin as a COX-2 inhibitor; the authors report in-vitro follow-up including COX-2 activity, cellular thermal-shift and surface-plasmon-resonance assays. This is a target-mechanism finding, not evidence of clinical efficacy.
Technology: MitoReID, deep-learning re-identification model using an Inflated 3D ResNet backbone on temporal mitochondrial images
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Among its natural-compound predictions, it nominated epicatechin as a COX-2 inhibitor; the authors report in-vitro follow-up including COX-2 activity, cellular thermal-shift and surface-plasmon-resonance assays.
- Still unknown: Evidence is biochemical/in-vitro and does not establish therapeutic efficacy or safety. MitoReID's six unseen-drug mechanism predictions are a separate task; the epicatechin COX-2 result is the specific new mechanistic finding recorded here. Full publisher page was cookie-blocked, but the primary PubMed record and publisher-indexed article text/extended-data caption were read.
- AI role: Ranked mechanisms of action for compounds by matching learned time-dependent mitochondrial phenotypes against reference drugs; the model nominated COX-2 inhibition for epicatechin, which was tested in vitro.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39169261/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 63 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
LSCNN ranked a combinatorial Ugi library after model development on focused activity data. The paper reports six active products among ten selected combinations against MRSA; purified H4–H6 had MIC and MBC of 12 μM. Different screening phases and cutoffs mean these figures are not a randomized general hit-rate comparison.
Technology: LSCNN feature-fusion neural network
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports 6/10 selected combinations active against MRSA and purified H4–H6 MIC/MBC results.
- Still unknown: Prior chemical-structure overlap, full independent replication, and clinical efficacy are not established.
- AI role: Model ranks products from combinatorial Ugi space for synthesis and testing.
Evidence sources: https://pubs.rsc.org/en/content/articlepdf/2024/sc/d3sc06441g · https://pmc.ncbi.nlm.nih.gov/articles/PMC11041243/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary source checked for identity, date, model role and bounded reported result..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
In a six-donor postmortem hippocampal study, neural cell segmentation and Spatial-ID annotation helped map Alzheimer-associated cell distributions and gene-expression changes. Immunofluorescence supported the inferred accumulation patterns of microglia and astrocytes around amyloid-beta plaques. These are observational associations, not causal effects or clinical benefit. This record describes the December 7, 2023 preprint; the later Neuron paper was published online March 31, 2025 with an expanded cohort, whose counts and final methods are not pooled here.
Technology: StereoCell/ESPANet cell segmentation; Spatial-ID deep neural network and graph convolutional network
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Spatial transcriptomics and single-nucleus sequencing in three AD and three control donor brains; immunofluorescence checked the plaque-associated glial distribution pattern within the same study.
- Still unknown: Postmortem observational results do not establish disease causation. No independent replication was assessed. Preprint methods retain an unfinished training-epoch placeholder. The reviewed claims and AI architectures refer to the primary preprint, not authenticated final journal methods; candidate blood biomarkers and diagnostic efficacy are outside this record's represented claim.
- AI role: Trained neural segmentation delineated cells; Spatial-ID used a DNN and GCN to assign spatial cell types, enabling plaque-associated cell-distribution analysis.
Evidence sources: https://www.medrxiv.org/content/10.1101/2023.12.06.23299593v1.full.pdf · https://www.medrxiv.org/content/10.1101/2023.12.06.23299593v1.full · https://pubmed.ncbi.nlm.nih.gov/40168986/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A sequential machine-learning pipeline screened virtual libraries of 6–9-residue peptides and identified three leading antimicrobial hexapeptides. The paper reports activity against multidrug-resistant clinical isolates and therapeutic effects in a mouse bacterial-pneumonia model. These are laboratory and animal results, not clinical efficacy.
Technology: Sequential machine-learning pipeline for peptide selection, classification, ranking and activity regression
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors report a sequential machine-learning pipeline over virtual 6–9 amino-acid sequence space; the leading three identified hexapeptides were tested against clinical multidrug-resistant isolates and in a mouse bacterial-pneumonia model.
- Still unknown: The mouse model and reported comparison with penicillin do not establish human efficacy. The PubMed primary metadata gives journal online date 2023-01-12; no earlier pre-2020 version is identified in the reviewed primary material.
- AI role: Sequential learned modules selected, classified, ranked and regressed peptide candidates from the virtual sequence library; the reported three lead hexapeptides are outputs of that workflow.
Evidence sources: https://www.nature.com/articles/s41551-022-00991-2 · https://pubmed.ncbi.nlm.nih.gov/36635418/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary Nature indexed article text and PubMed abstract/metadata/affiliation record for the ML hexapeptide screening study, its January 2023 publication date and reported mouse pneumonia assays..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.